About Venn

A trusted partner in the life science industry for over 25 years

Venn Life Sciences is an Integrated Drug Development partner offering a unique combination of drug development consultancy, clinical trial design and execution.

These carefully combined services enable us to provide our customers with a complete service on all the stages of their drug development programs, from the early planning phase to final execution.

Venn Life Sciences features offices in Breda (Netherlands) and Paris (France) that offer expertise and capabilities in: CMC, Non-Clinical, Clinical Pharmacology and Development, Statistics, Study design and Methodology, Data Management, RTSM and Regulatory Affairs across a wide variety of therapeutic areas.

Expediting the development of Biopharma projects worldwide.

For over 25 years we have been a trusted partner to the life science industry. In recent years, we have developed our services and offering by acquiring Kinesis Pharma in 2015 and becoming part of Open Orphan, a rapidly growing niche CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. In 2022, Open Orphan has rebranded to hVIVO. Venn Life Sciences has longevity within the industry and has a team of motivated experts, which combined expedites the development of Biopharma projects worldwide.

Our mission is to deliver high quality drug and device development services to our customers across their product development life cycle.

We play a pivotal role in the development of new products, enabling disease prevention and treatment through:
Long term partnerships
Providing comprehensive added-value services in the long-term.
Anticipating customer needs
Development and integration of new services anticipated by customer needs.
Operational Excellence
Ensuring operational excellence across our service lines

Our team of experts can generate opportunities and support through the various stages of development.

Meet the Team

Discover the development of Venn Life Sciences

Open Orphan rebranded to hVIVO, therefore Venn becoming, Venn - part of hVIVO


Venn announces partnership and takeover by Open Orphan

2018 & 2019


Full integration of services from Early Phase to Late Phase Drug Development.

Stock Market

Venn is listed as a public company on ISE.

Venn Opens Paris Office

March 2016

Acquisition of Kinesis Pharma BV

October 2015

Acquisition of Cardinal Systems SAS

Cardinal Systems SAS (founded in 1996).
August 2014

Acquisition of Clinical Trials GmbH

Acquisition of German based CRO, CRM Clinical Trials GmbH (founded in 1996).
October 2013

Takeover of Armscote

Takeover of Armscote Investment Company Plc by Venn Life Sciences AIM IPO.
December 2012

Stock Market

Venn is listed as a public company on AIM.

Venn Life Sciences is formed



Venn The Netherlands set up under the name UPTOYOU.

Ready to see how Venn Life Sciences could speed up your drug development program?
Get in touch.

Contact Venn